Monday, October 9, 2017


CAPR Capricor Therapeutics, Inc. gains 91% Oct 9, 2017

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 and enderitide, which are in Phase II clinical trials, as well as CAP-1001, which has completed Phase I clinical trial; and CU-NP and CSps. It is also developing Exosomes for the treatment of cardiovascular and non-cardiovascular diseases. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive